Siegfried Sales Grew to CHF 633 Million in First Half
The manufacturer expanded its global footprint through acquisitions and new capacity to meet service demand.
Updated on Sept. 24, 2026 in Corporate Finance
Live Poll
Do you trust large pharmaceutical companies to successfully manage international growth through corporate acquisitions?
Siegfried reported net sales of CHF 633 million for the first half of 2026, marking a 4.8% year-over-year increase in local currencies. The company continues to execute its EVOLVE+ strategy, which emphasizes operational excellence and targeted acquisitions to drive performance.
Why it matters
The company’s growth is underpinned by sustained demand for outsourced development and manufacturing services. Operational scalability, bolstered by new facilities and recent asset purchases, remains the primary lever for maintaining margins in this specialized sector.
Siegfried reported first-half 2026 net sales of CHF 633 million, representing a 4.8% increase in local currencies compared to the prior year. The firm achieved a 22.4% core EBITDA margin on CHF 142 million in earnings, while forecasting USD 100 million in annual sales from newly acquired assets.
The players
Siegfried
A global contract development and manufacturing organization that provides drug substance and product services to the pharmaceutical industry.
DINAMIQS
A subsidiary of Siegfried specializing in viral vector production and advanced gene therapy development.
Swissmedic
The Swiss regulatory agency responsible for the oversight and licensing of medicinal products and therapeutic manufacturing.
The details
Siegfried’s operational growth follows the May 1, 2026, acquisition of three drug substance manufacturing sites across the U.S. and Australia. Additionally, the company inaugurated a large-scale manufacturing facility in Minden in June 2026, adding 100 m³ of reactor capacity to its production network. These expansions, coupled with a new viral vector production license for subsidiary DINAMIQS, allow the company to capture higher volume demand in drug substance and product markets.
Timeline
May 1, 2026: The company completed the acquisition of three drug substance manufacturing sites.
June 2026: A large-scale manufacturing facility was inaugurated in Minden.
First half 2026: This period reflects the reported financial performance results.
Market Landscape
Siegfried’s growth aligns with the documented industry trend of pharmaceutical firms increasingly relying on contract development and manufacturing organizations (CDMOs) for specialized production. This move follows a sector-wide pattern of infrastructure investment and capacity consolidation to capture market share.
Operators should monitor Siegfried’s 2026 core EBITDA margin targets of above 23% as a benchmark for operational efficiency in high-cap manufacturing. Firms evaluating outsourcing partners should assess how similar capacity expansions impact vendor lead times and service availability in the coming months.
The takeaway
Siegfried’s results highlight the effectiveness of integrating localized manufacturing nodes to support scaling service demand. Operators should track the performance of the USD 100 million sales contribution from new sites to gauge the real-world success of these recent capital investments.
Further reading
For more on industry consolidation, visit /finance/corporate-finance/.
Source note: This article includes information reported by Pharmaceuticalonline.
Live Poll
Do you trust large pharmaceutical companies to successfully manage international growth through corporate acquisitions?
